



**Primary Immunodeficiency Diseases Consortium Conference
June 11, 2009
San Francisco, CA, USA**

Final Report

Overview

The Primary Immunodeficiency Diseases Consortium Conference took place at the San Francisco Marriott in San Francisco, CA, on June 11, 2009, in conjunction with the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting. This was the fifth Consortium on Primary Immunodeficiency Diseases.

This year's Consortium was co-organized by the Clinical Immunology Society (CIS) and the American Academy of Allergy, Asthma, & Immunology (AAAAI).

This activity was intended to reach an international target audience consisting of fellows-in-training, junior faculty, as well as noted experts in the field.

This symposium brought together experts in the field to discuss recent updates as well as material related to our understanding of the scientific processes affected in various primary immune deficiencies. Both by lecture and networking during the symposium, clinicians and researchers came away with an improved knowledge of primary immunodeficiencies. The material was delivered primarily in lecture format; however a poster session and scheduled breaks allowed networking, mentoring, and one-on-one time with the state-of-the art lecturers.

The objectives for this conference were: to continue to advance understanding of the diagnosis, molecular defects, complications, and treatment of these complex diseases; to develop the careers of new scientists in this area of academic medicine; to enhance awareness of clinical immunology and its importance in scientific discoveries and clinical applications; and to stimulate future collaborations between investigators in different medical centers and countries, and between new investigators and experienced physician / scientists in the field.

Organizers

Six organizers were selected to review applications and attend the Consortium. The organizers consisted of the following members:

Charlotte Cunningham-Rundles, MD PhD • Mount Sinai Medical Center • New York, NY
Kari Nadeau, MD PhD • Stanford University • Stanford, CA
Hans Ochs, MD • University of Washington • Seattle, WA
Joao Bosco Oliveira, MD PhD • National Institutes of Health • Bethesda, MD
Kathleen Sullivan, MD PhD • Children's Hospital of Philadelphia • Philadelphia, PA
Troy Torgerson, MD PhD • University of Washington • Seattle, WA

Advertisement

This program was advertised on the Clinical Immunology Society (CIS) website and to CIS members via email announcements. The AAAAI also posted the information and additional announcements were sent via email to the AAAAI training program directors and posted on a fellow-in-training list serve. ESID and the USIDNET also promoted the Consortium through their web site. FOCIS posted the information on their web site and sent out announcements to their member societies.

Applications/Selection Process

CIS contracts with Scholar One to provide an on-line abstract submission site specifically designed for the Consortium Conference. Interested applicants will create an account within the on-line site and upload their abstract and any supporting documents that may be required. Abstracts are submitted on the topic of primary immune deficiency and are then reviewed by the Organizers. An emphasis is placed on including women and minorities among the organizers as well as physicians in each specialty relating to primary immune deficiency. Once the abstract submission has closed, the organizers are provided access to all submitted applications for review. They score each application based on the credentials of the candidate and the amount of interest in the abstract. The organizers score the abstracts on a 1-5 scale, with 1 being the lowest score and 5 being the highest score. There is also a mechanism for abstract reviewers to disqualify themselves from scoring the abstract due to a conflict of interest. After all abstracts are scored, the scores are averaged and sent back to the organizers. The top nine abstract authors were selected to present an oral presentation and the following top 42 were selected to present a poster.

Participants

Fourteen speakers, including the abstract presenters, were invited to present at the Consortium along with over forty poster presenters.

Countries represented by the oral presenters included:

- Brazil
- Germany
- The Netherlands
- United States

CIS provided travel grants for all accepted oral and poster presenters to attend the Consortium.

Program

This program was a full day satellite. Fourteen speakers were invited to present on their area of expertise, which included nine abstracts selected for an oral presentation. Sufficient time was allocated after each presentation for a question and answer session. A Poster Reception was held during lunch for those abstracts selected to allow for additional networking.

This activity was planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the sponsorship of the Clinical Immunology Society. The Clinical Immunology Society is accredited by the ACCME to

provide continuing medical education for physicians. The Clinical Immunology Society designated this educational activity for a maximum of 6 *AMA PRA Category 1 Credits™*.

A complete schedule of events with topics and presenters is below.

Schedule of Events

- 8:00 am *Welcome & Introduction*
Charlotte Cunningham-Rundles, MD PhD
Mt. Sinai Medical Center
Kathleen Sullivan, MD PhD
Children's Hospital of Philadelphia
- 8:15 am *Murine Forward Genetics Approach in Identifying a Novel Human SCID Gene*
Lawrence Shiow, PhD
University of California San Francisco
- 8:45 am *Clinical Phenotype and Long Term Outcome in Large Cohort of XLT / Mild Wiskott-Aldrich Syndrome Patients*
Michael Albert, MD
Dr. von Haunersches Kinderspital der LMU, Germany
- 9:05 am *Decrease in Class-switched Memory B Cells is Associated with Malignancy in CVID*
Avni Joshi, MD
Mayo Clinic
- 9:55 am *Identifying Biomarkers in ALPS: Serum Vitamin B12 and Plasma IL-10 Levels as Potential Diagnostic Tools*
Joao Bosco Oliveira, MD PhD
National Institutes of Health
- 10:15 am *Foxp3 Expression in Human T Cells does not Require Thymic Function*
Ivan Chinn, MD
Duke University Medical Center
- 10:35 am *Somatic Mosaicism for STAT3 Mutation Unveils Critical Role in Human T-cell Memory Development and B-cell Help*
Joshua Milner, MD
NIAID
- 10:55 am Keynote Presentation:
Innate Signals in Mucosal Ig Heavy Chain Class Switching
Andrea Cerutti, MD
Weill Medical College of Cornell University
- 11:40 am Panel Discussion
- 12:00 pm Lunch / Poster Session
Yerba Buena Ballroom Salon 9

- 1:30 pm *Role of SAP in iNKT Cell Cytokine Production and Cytotoxicity*
Hamid Bassiri, MD PhD
Children's Hospital of Philadelphia
- 1:50 pm *LRRC8 Activation Results in MAP/SAP Kinase Phosphorylation*
Janet Chou, MD
Children's Hospital Boston, Harvard Medical School
- 2:10 pm *Evidence of Altered Calcium Signaling in a Case of Hereditary Multiple Intestinal Atresia with Immunodeficiency*
Karin Chen, MD
David Geffen School of Medicine at UCLA
- 2:30 pm *Antisense-mediated Exon Skipping to Correct IL-12R β 1 Deficiency in T Cells*
Esther Van de Vosse, PhD
Leiden University Medical Center, Netherlands
- 3:20 pm *Prevalence and Functional Significance of Anti-Cytokine Autoantibodies in Thymoma*
Sarah Browne, MD
NIAID
- 3:40 pm *Immunosuppressive Human Anti-lymphocyte Autoantibodies that Selectively Inhibit T-cell Trafficking*
Katharine Fast, MD
University of California, San Francisco
- 4:00 pm *Gene Therapy for Primary Immune Deficiency Diseases*
Donald B. Kohn, MD
University of California, Los Angeles

Evaluation Results

2009 Primary Immunodeficiency Diseases Consortium Conference Evaluation Results

1. How did you hear about the PID Consortium? (Please select all that apply)
- A. Email from CIS: 6
 - B. Email from FOCIS: 4
 - C. Past attendee: 4
 - D. CIS web site: 5
 - E. FOCIS web site: 6
 - F. Other: 1

Please circle the number that best describes your agreement with each statement.

2. The program fulfilled the following learning objectives:	Strongly Agree	Agree	Neither Agree nor Disagree	Disagree	Strongly Disagree
A.) advanced understanding of the diagnosis, molecular defects, complication, and treatment of these complex diseases;	75% (9)	25% (3)	-	-	-
B.) aided in developing the careers of new scientists in this area of academic medicine;	62% (8)	31% (4)	8% (1)	-	-
C.) enhanced awareness of clinical immunology and its importance in scientific discoveries and clinical applications;	67% (8)	25% (3)	8% (1)	-	-
D.) stimulated future collaborations between investigators in different medical centers and countries, and between new investigators and experienced physician/scientists in the field.	73% (8)	9% (1)	18% (2)	-	-
3. The content of the program was relevant to my educational needs.	77% (10)	15% (2)	8% (1)	-	-
4. The lectures were free of commercial bias.	100% (13)	-	-	-	-
5. Sufficient time was allocated for questions, answers, and discussion.	77% (10)	15% (2)	8% (1)	-	-

6. Additional Comments:

- Excellent talks and well selected topics.
- Fabulous, best yet.
- Give more clinics.
- Great mix of science & clinical.
- Great organization, well run.
- Not all talks directly relevant to PID
- Very good session.
- Excellent selection of young speakers overall.

7. Topic Suggestions for Future Educational Programs:

- Continue to invite their top people to talk.

- Discuss the importance of educational programs in the physician's graduation.
- Interface of Autoimmunity & Immune Deficiency.

Corporate and Government Support

Grants from the following companies and government agencies enabled CIS and AAAAI to conduct this consortium:

Baxter Biosciences
CSL Behring
National Institutes of Health
Octapharma USA, Inc.
Office of Rare Diseases - NIH
Talecris Biotherapeutics